Search Results - Joachim Yahalom

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis

    Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis by Mohammad Alhomoud, Rahma Ibrahim, Michelle Demetres, Kai Rejeski, Michael Scordo, Roni Shouval, Tobias Tix, Jeremie Martinet, Michelle Foley, Alexandra Gomez-Arteaga, Tsiporah Shore, Paul Pagnini, Mahmoud Aljurf, Monica L. Guzman, Silvia Formenti, Joachim Yahalom, Koen van Besien, Brandon S. Imber, Zhengming Chen, Samuel Yamshon

    Published 2025-07-01

    Bridging radiation therapy (BRT) is increasingly utilized prior to CART19 in NHL patients. However, its impact on CART19 outcomes is not established. We conducted a systematic review and meta-analysis to estimate the safety and efficacy of BRT prior to CART19 therapy. A comprehensive search was per...

    Full description

    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study

    Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study by Nikhil Yegya-Raman, John P. Plastaras, Christopher M. Wright, Monica Chelius, Siqi Zhang, Jonathan A. Baron, Harper Hubbeling, Austin J. Sim, Timothy J. Robinson, Michael D. Jain, Brandon Imber, Beatrice Fregonese, Joachim Yahalom, Colton Ladbury, Savita Dandapani, Chelsea C. Pinnix, Jillian R. Gunther, Penny Q. Fang, Susan Y. Wu, Bouthaina S. Dabaja, Joanna C. Yang, Jessica Chew, Steve Braunstein, Sumi Sinha, Nathan M. Delinger, Susan Sun, Stephanie A. Terezakis, Gukan Sakthivel, Louis S. Constine, Amit K. Chowdhry, Patrick M. Reagan, Skyler Burke, Yolanda D. Tseng, Michael J. LaRiviere, Amit Maity, Stephen J. Schuster, Elise A. Chong, Nicholas B. Figura

    Published 2025-07-01

    Abstract: Despite the increasing utilization of bridging radiotherapy (Br-RT), its impact on chimeric antigen receptor T-cell therapy (CAR-T) efficacy and toxicity remains poorly characterized. We retrospectively reviewed patients with relapsed/refractory B-cell lymphomas (BCLs) who received Br-RT f...

    Full description

    Get full text
    Article

    Save to List
    Saved in:

Search Tools: